Evidence map›Paper›PMID 39343571›Full record

Observational studyInternal medicine (Tokyo, Japan)2024

Clinical Course and Factors Correlated with Severe Morbidity and Mortality in Patients with Coronavirus Disease 2019 Undergoing Maintenance Dialysis in Kanagawa, Japan.

Kohei Ishiga, Hiromichi Wakui, Kengo Azushima, Tomohiko Kanaoka, Daisuke Kanai, Ryu Kobayashi, Sho Kinguchi, Naohito Okami, Tatsuya Haze, Takehisa Iwano and 10 more

Abstract readObservational StudyMulticenter Study
In one paragraph

Observational study in Internal medicine (Tokyo, Japan), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Kohei IshigaDepartment of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Japan.
Hiromichi WakuiDepartment of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Japan.
Kengo AzushimaDepartment of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Japan.
Tomohiko KanaokaDepartment of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Japan.
Daisuke KanaiDepartment of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Japan.
Ryu KobayashiDepartment of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Japan.
Sho KinguchiDepartment of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Japan.
Naohito OkamiDepartment of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Japan.
Tatsuya HazeYCU Center for Novel and Exploratory Clinical Trials (Y-NEXT), Yokohama City University Hospital, Japan.
Takehisa IwanoDepartment of Nephrology, Yokohama Minami Kyosai Hospital, Japan.
Masashi SakaiDepartment of Nephrology, Fujisawa City Hospital, Japan.
Kohji OhkiYokodai Central Clinic, Japan.
Jin OshikawaDepartment of Nephrology, Yokohama Sakae Kyosai Hospital, Japan.
Toshiharu KokuhoDepartment of Renal Medicine, Yokosuka City Hospital, Japan.
Masaaki HanaokaDepartment of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Japan.
Hiroshi MitsuhashiKohsaikai Yokohama Jinsei Hospital, Japan.
Yukiko YamadaKohsaikai Kamioooka Jinsei Clinic, Japan.
Machiko YabanaDepartment of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Japan.
Yoshiyuki ToyaDepartment of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Japan.
Kouichi TamuraDepartment of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective Patients undergoing maintenance dialysis are at a higher risk of morbidity and mortality due to severe coronavirus disease 2019 (COVID-19) than the general population. However, longitudinal data regarding this subpopulation of patients are lacking. We therefore examined the prognosis of patients with COVID-19 undergoing maintenance dialysis between 2020 and 2023. In addition, we explored the factors correlated with COVID-19 severity, focusing on the transition thereof throughout the observational period. Methods The primary outcome was the progression to severe or fatal COVID-19. We evaluated the correlation between the primary outcome and baseline demographic and clinical characteristics of patients. Patients undergoing maintenance dialysis who were hospitalized for mild-to-moderate COVID-19 between February 2020 and April 2023 were enrolled at four institutions in Kanagawa, Japan. Results Of the 173 patients, 7 (4.0%) developed severe COVID-19, and 12 (6.9%) died. The severe/death cohort was significantly older, with a higher percentage of unvaccinated patients than the non-severe cohort (58.2% and 25.0%, respectively; p=0.016). Thymus and activation-regulated chemokine levels on admission were lower in the severe/death cohort than in the non-severe cohort, albeit not to a statistically significant degree (148±84 mg/dL and 342±657 pg/mL, respectively; p=0.082). A multivariate logistic regression analysis revealed that the odds ratio for severe morbidity or death was 0.23 (95% confidence interval: 0.07-0.75) for vaccinated patients. Conclusion In patients undergoing maintenance dialysis, the severity rate of COVID-19 is approximately 10%. Vaccination was correlated with a reduced risk of severe COVID-19.

Indexed as

COVID-19Renal DialysisSeverity of Illness IndexAgedAged, 80 and overDisease ProgressionFemaleHumansJapanMaleMiddle AgedPrognosisRisk FactorsSARS-CoV-2COVID-19dialysisJapanseverityvaccination

Identifiers

PMID39343571
PMCPMC11671206

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.